New Pharmaceutical Labeling Rules Proposed in Brazil
Friday, April 10th, 2009Brazil’s National Sanitary Vigilance Agency (ANVISA) is proposing changes in package labeling rules for pharmaceuticals sold in that country (as set out in ANVISA Resolution RDC 333/03) with a view to making pack labels more informative to consumers. For example, the proposals released for public consultation (until 11 May) would make medicines with a sedative […]
An Andean Medicines Policy
Sunday, March 29th, 2009Last Friday the 30th Meeting of the Health Ministers of the Andean Area (RMSAA) agreed on other important health measures — a coordinated epidemiological surveillance system, joint plans to combat HIV/AIDS, protect health in border areas and to combat child malnutrition — but the one that caught my eye was the new Andean Medicines Policy. […]
DR & Central America Agree on Common Health, Pharma Policies/Programs
Saturday, January 31st, 2009It doesn’t get much attention outside this corner of Latin America and the Caribbean (LAC), but the annual Meeting of the Health Sector of Central America and the Dominican Republic (Reunión del Sector Salud de Centro América y República Dominicana – RESSCAD) is quietly doing important work to change health policy among its seven member […]
An Affordable Anti-Malarial / Um medicamento para malária a preço mais acessível
Wednesday, August 20th, 2008From Drugs for Neglected Diseases initiative (DNDi): Sanofi-aventis and DNDi welcome the Clinton Foundation announcement on ACTs and commit to providing fixed-dose combination “ASAQ” at equally low prices Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) welcome the agreement announced by Clinton Foundation HIV/AIDS Initiative (CHAI) to reduce the volatility and the price […]
The Need to Improve the Safety of Children’s Medicines
Friday, September 28th, 2007Pharmacovigilance and medicine safety issues in children are relevant to everyone who has an interest in and cares about the health of children. In order to gain full marketing authorization, the law in most countries requires pharmaceutical firms to demonstrate that they have tested their medicines in healthy volunteers and patients for possible adverse effects. […]